Abstract: Described are implantable devices and methods for treating various disorders of the pelvic floor by means of electrical stimulation of the left and right sacral nerves, or portions thereof. Two or more electrical stimulation regimes are applied on a continuous, alternating, intermittent or other basis to the left and right sacral nerves or nerve portions in an amount and manner effective to treat a number of disorders, including, but not limited to, urinary and/or fecal voiding dysfunctions such as constipation, incontinence disorders such as urge frequency and urinary retention disorders, sexual dysfunctions such as orgasmic and erectile dysfunction, pelvic pain, prostatitis, prostatalgia and prostatodynia.

Abstract: Described are implantable devices and methods for treating various disorders of the pelvic floor by means of electrical stimulation of the left and right sacral nerves, or portions thereof. Two or more electrical stimulation regimes are applied on a continuous, alternating, intermittent or other basis to the left and right sacral nerves or nerve portions in an amount and manner effective to treat a number of disorders, including, but not limited to, urinary and/or fecal voiding dysfunctions such as constipation, incontinence disorders such as urge frequency and urinary retention disorders, sexual dysfunctions such as orgasmic and erectile dysfunction, pelvic pain, prostatitis, prostatalgia and prostatodynia.

Abstract: Described are implantable devices and methods for treating various disorders of the pelvic floor by delivering one or more drugs to at least two pudendal nerves or nerve portions. One, two or more drug delivery regimes are provided on a continuous, alternating, intermittent or other basis to first and second pudendal nerves or nerve portions in an amount and manner effective to treat a number of disorders, including, but not limited to, urinary and/or fecal voiding dysfunctions such as constipation, incontinence disorders such as urge frequency and urinary retention disorders, sexual dysfunctions such as orgasmic and erectile dysfunction, pelvic pain, prostatitis, prostatalgia and prostatodynia.

Abstract: Described are implantable devices and methods for treating various disorders of the pelvic floor by delivering one or more drugs to a sacral nerve or nerve portion, as well as to a pudendal nerve or nerve portion. Two or more drug delivery regimes are provided on a continuous, alternating, intermittent or other basis to the sacral and pudendal nerves in an amount and manner effective to treat a number of disorders, including, but not limited to, urinary and/or fecal voiding dysfunctions such as constipation, incontinence disorders such as urge frequency and urinary retention disorders, sexual dysfunctions such as orgasmic and erectile dysfunction, pelvic pain, prostatitis, prostatalgia and prostatodynia.

Abstract: Described are devices and methods for treating various disorders of the pelvic floor by means of electrical stimulation of the pudendal nerves, and means for delivering one or more drugs in association with such electrical stimulation therapies. One or more electrical stimulation signals are applied, and one or more drugs are infused, injected or otherwise administered, to appropriate portions of a patient's pelvic floor and the pudendal nerves or portions thereof in an amount and manner effective to treat a number of disorders, including, but not limited to, urinary voiding dysfunction, fecal voiding dysfunction, constipation, stress incontinence, urge incontinence, urinary retention disorder, sexual dysfunction, orgasmic dysfunction, erectile dysfunction, pelvic pain, prostatitis, prostatalgia and prostatodynia.

Abstract: Described are devices and methods for treating various disorders of the pelvic floor by means of electrical stimulation of the pudendal and sacral nerves, and means for delivering one or more drug in association with such electrical stimulation therapies. One or more electrical stimulation signals are applied, and one or more drugs are infused, injected or otherwise administered, to appropriate portions of a patient's pelvic floor and pudendal and sacral nerves or portions thereof in an amount and manner effective to treat a number of disorders, including, but not limited to, urinary voiding dysfunction, fecal voiding dysfunction, constipation, stress incontinence, urge incontinence, urinary retention disorder, sexual dysfunction, orgasmic dysfunction, erectile dysfunction, pelvic pain, prostatitis, prostatalgia and prostatodynia.

Abstract: Described are implantable devices and methods for treating various disorders of the pelvic floor by delivering one or more drugs to a patient's hypogastric nerve or branches or portions thereof, prostatic plexus nerve or branches or portions thereof, sacral splanchnic nerve or branches or portions thereof, pelvic splanchnic nerve or branches or portions thereof, prostate or branches or portions thereof, pelvic floor, colon or branches or portions thereof, bladder or portions thereof, vagina or portions thereof, anus or portions thereof, external anal sphincter or portions thereof, urethra or portions thereof, penile dorsal nerve or portions thereof, inferior rectal nerves or branches or portions thereof, perineal nerves or branches or portions thereof, scrotal nerves or branches or portions thereof, scrotum or portions thereof, Alcock's Canal or branches or portions thereof, sacro-tuberous ligament or branches or portions thereof, ischial tuberosity or branches or portions thereof, greater sciatic foramen or

Abstract: Described are combinations of implantable and external means for providing pain relief to patients suffering from prostatitis, prostatalgia or prostatodynia which employ electrical and/or magnetic stimulation to effect such relief. Implantable medical electrical leads or wireless modules comprising one or more electrodes deliver electrical stimulation to a selected site of a patient adjacent, around or in one of the sacral nerve or branches or portions thereof, the pudendal nerve or branches or portions thereof, the hypogastric nerve or branches or portions thereof, the prostatic plexus nerve or branches or portions thereof, the sacral splanchnic nerve or branches or portions thereof, or the pelvic splanchnic nerve or branches or portions thereof in an amount or degree sufficient to provide at least partial relief from pain intramuscular lead system. Optionally, an external or internal drug pump may be employed in conjunction with the electrical stimulation provided to the patient.

Abstract: Assembly and method for measuring the concentration of an analyte in a biological matrix. The assembly includes an implantable optical-sensing element that comprises a body, and a membrane mounted on the body in a manner such that the membrane and the body define a cavity. The membrane is permeable to the analyte, but is impermeable to background species in the biological matrix. A refractive element is positioned in the cavity. A light source transmits light of a first intensity onto the refractive element, and a light detector receives light of a second intensity that is reflected from the cavity. A controller device optically coupled to the detector compares the first and second light intensities, and relates the intensities to analyte concentration.

Abstract: An optical send-receive module includes a frame which has a front section, a back side, and a top section. A lens carrier is attached to the front section of the frame. The lens carrier includes one or more lenses which face forward. An integrated circuit carrier is placed within the top section of the frame. First metal leads electrically connect components within the lens carrier to an integrated circuit within the integrated circuit carrier. Second metal leads extend from the integrated circuit carrier, along the top section of the frame, down the back side of the frame and are bent under the frame.

Abstract: The present invention provides a process for the specific determination of pancreatic alpha-amylase in the presence of salivary alpha-amylase in body fluids, especially in serum, plasma, duodenal juice or urine, by reaction with a system for the detection of alpha-amylase in the presence of a monoclonal antibody which inhibits salivary alpha-amylase wherein, as inhibitor, there is used a first monoclonal antibody which specifically inhibits the salivary enzyme by less than 97%, in combination with a second monoclonal anti-saliva alpha-amylase antibody which inhibits this enzyme by less than 10%.

Abstract: Alkaline phosphatase to which is covalently bound a carbohydrate of the general formula ##STR1## wherein n is 0, 1, 2 or 3, A is an acyl radical containing 2 to 5 carbon atoms, R.sup.1 and R.sup.2 are each hydrogen atoms or hydroxyl groups, R.sup.3 is --COOH or --CH.sub.2 OH, R.sup.4 is a hydroxyl group or a --CHOH--CHOH--CH.sub.2 OH or --NH--CO--CH.sub.2 --CH(NH.sub.2)--COOH radical or a complex containing the carbohydrate, is used as a standard for the determination of human alkaline phosphate. Preferred carbohydrates are ovomucoid, chitobiose, chitotriose or N-acetylglucosamine-N-acetylneuraminic acid.

Abstract: Pancreatic .alpha.-amylase is determined in body fluid in the presence of salivary .alpha.-amylase by combining the body fluid with a monoclonal antibody that inhibits salivary .alpha.-amylase by 95% or more and inhibits pancreatic .alpha.-amylase by 50% or less, and then detecting pancreatic .alpha.-amylase with a system for the detection of .alpha.-amylase. The monoclonal antibody may be in immobilized form. The monoclonal antibody is preferably produced by immunizing a Balb/c mouse or an AJ mouse with a specific immunogen for a specific number of times, fusing .beta.-lymphocytes obtained from the mouse with a myeloma cell line to form an antibody producing hybridoma cell line, cloning and screening the hybridoma cell line for the desired monoclonal antibody, and isolating the monoclonal antibody. The immunogen contains modified or unmodified salivary .alpha.-amylase, aluminum hydroxide and Bortadella pertussis.

Abstract: The present invention provides a process for the determination of .alpha.-amylase by cleavage of a substrate in the presence of one or more auxiliary enzymes and measurement of a cleavage product, wherein the reaction is carried out in the presence of monoclonal antibodies against .alpha.-amylase.The present invention also provides a reagent for the determination of .alpha.-amylase containing a substrate, one or more auxiliary enzymes and a system for the measurement of a cleavage product, wherein it also contains at least one monoclonal antibody against .alpha.-amylase.

Abstract: The present invention provides a monoclonal anti-alpha-amylase antibody which non-specifically inhibits the enzyme activity of human alpha-amylase by more than 90%.The present invention also provides a process for obtaining this monoclonal antibody and a medicament containing it.